Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
3.77
Dollar change
+0.04
Percentage change
1.07
%
Index- P/E- EPS (ttm)-1.71 Insider Own12.78% Shs Outstand20.46M Perf Week-13.73%
Market Cap77.13M Forward P/E- EPS next Y-1.27 Insider Trans-0.08% Shs Float17.84M Perf Month-15.47%
Income-22.27M PEG- EPS next Q-0.31 Inst Own7.57% Short Float0.88% Perf Quarter36.10%
Sales0.06M P/S1285.57 EPS this Y28.22% Inst Trans9.33% Short Ratio0.90 Perf Half Y17.45%
Book/sh0.78 P/B4.86 EPS next Y-3.46% ROA-104.28% Short Interest0.16M Perf Year-19.44%
Cash/sh0.82 P/C4.59 EPS next 5Y- ROE-141.57% 52W Range2.00 - 6.19 Perf YTD15.47%
Dividend Est.- P/FCF- EPS past 5Y-79.01% ROI-167.97% 52W High-39.10% Beta0.43
Dividend TTM- Quick Ratio3.59 Sales past 5Y93.18% Gross Margin-51.47% 52W Low88.50% ATR (14)0.34
Dividend Ex-Date- Current Ratio3.59 EPS Y/Y TTM-15.79% Oper. Margin-40328.26% RSI (14)36.55 Volatility11.78% 7.51%
Employees32 Debt/Eq0.08 Sales Y/Y TTM-60.62% Profit Margin-40354.33% Recom1.00 Target Price8.75
Option/ShortYes / Yes LT Debt/Eq0.05 EPS Q/Q25.90% Payout- Rel Volume0.58 Prev Close3.73
Sales Surprise33.32% EPS Surprise7.05% Sales Q/Q- EarningsMar 27 BMO Avg Volume174.92K Price3.77
SMA20-13.74% SMA50-11.46% SMA2003.43% Trades Volume102,211 Change1.07%
Date Action Analyst Rating Change Price Target Change
Apr-12-21Initiated Oppenheimer Outperform $30
Apr-12-21Initiated BTIG Research Buy $30
Mar-26-24 01:53PM
08:00AM
Mar-15-24 02:30PM
Mar-05-24 09:45AM
08:00AM
02:00PM Loading…
Feb-27-24 02:00PM
Feb-14-24 12:29PM
Feb-06-24 09:56AM
08:00AM
Jan-31-24 08:00AM
Jan-24-24 12:00PM
Jan-02-24 08:00AM
Dec-14-23 09:55AM
Dec-04-23 08:00AM
Dec-01-23 08:00AM
08:00AM Loading…
Nov-29-23 08:00AM
Nov-24-23 01:01PM
Nov-22-23 11:58AM
Nov-21-23 08:54AM
Nov-20-23 04:03PM
Nov-14-23 07:00AM
Oct-04-23 08:45AM
07:00AM
Sep-25-23 04:05PM
Sep-20-23 04:05PM
Sep-12-23 09:25AM
Aug-29-23 08:57AM
Aug-28-23 07:00AM
Aug-10-23 08:25AM
07:00AM
07:00AM Loading…
Aug-07-23 07:00AM
Jul-31-23 08:00AM
Jun-01-23 08:00AM
May-13-23 08:09AM
May-12-23 09:15AM
08:00AM
May-08-23 10:00AM
May-03-23 09:15AM
Apr-12-23 04:30PM
Mar-29-23 08:52AM
Mar-23-23 04:05PM
Mar-22-23 08:30AM
Mar-21-23 08:00AM
Mar-09-23 08:00AM
Feb-27-23 08:00AM
Feb-02-23 08:00AM
Jan-17-23 10:00AM
Jan-12-23 04:05PM
Nov-10-22 05:15PM
04:02PM
Sep-26-22 11:59AM
08:00AM
Sep-20-22 07:30AM
Sep-19-22 08:00AM
Sep-08-22 08:00AM
Sep-06-22 08:00AM
Aug-08-22 09:15AM
08:00AM
Aug-04-22 08:00AM
Aug-03-22 10:00AM
Jun-02-22 08:00AM
May-18-22 08:00AM
May-16-22 05:55PM
04:05PM
May-11-22 09:30AM
May-06-22 08:00AM
May-03-22 08:31AM
May-02-22 03:00PM
Apr-26-22 05:19PM
Apr-12-22 01:00PM
Mar-29-22 08:00AM
Mar-24-22 08:00AM
Mar-15-22 08:00AM
Mar-01-22 08:00AM
Feb-08-22 08:00AM
Feb-04-22 12:06PM
Jan-31-22 04:05PM
Jan-18-22 08:00AM
Jan-06-22 04:05PM
Dec-28-21 04:05PM
Dec-16-21 06:57AM
Dec-07-21 08:00AM
Dec-01-21 04:07PM
Nov-12-21 09:52AM
07:00AM
Nov-11-21 11:00AM
Nov-10-21 11:00AM
Nov-04-21 04:05PM
Oct-28-21 08:00AM
Oct-26-21 08:00AM
Oct-19-21 08:00AM
Oct-12-21 10:07AM
Sep-23-21 08:00AM
Sep-17-21 08:00AM
Sep-09-21 04:20PM
Sep-08-21 03:51PM
11:42AM
09:08AM
Sep-02-21 04:05PM
Aug-11-21 04:01PM
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Alder MatthiasChief Executive OfficerDec 21 '23Sale2.462065075,286Dec 22 04:17 PM
Alder MatthiasChief Executive OfficerDec 07 '23Sale2.501,8204,5504,855Dec 14 04:01 PM